Principal Investigator
Birte Wistinghausen
Children's Oncology Group
Total Trials
1
As PI
1
Completed
1
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
MIXED(1)
BIOLOGICAL(1)
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
1 trial
phase_2
childrens-oncology-groupRituximab
1 trial
phase_2
childrens-oncology-group2 unique interventions2 categories
Analytics
Trial Phases
Phase 21
Trial Status
Completed1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative DisorderMonomorphic Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder+4 more
PrincipalinvestigatorStart date: 2017-03-22
Research Network
Collaboration Network
1 collaborators·0 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
EBV-Related Post-Transplant Lymphoproliferative Disorder1Monomorphic Post-Transplant Lymphoproliferative Disorder1Polymorphic Post-Transplant Lymphoproliferative Disorder1Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder1Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder1Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder1Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder1
Affiliations
Children's Oncology Group
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
3 similar investigators found
Timothy J Voorhees, MD
Ohio State University Comprehensive Cancer Center
2 trials
Shared therapeutic areas:
EBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative DisorderRecurrent Polymorphic Post-Transplant Lymphoproliferative Disorder+2 more
Worked with same sponsors:
National Cancer Institute (NCI)
Similarity Score21%
Timothy J Voorhees, MD, MSCR
Ohio State University Comprehensive Cancer Center
2 trials
Shared therapeutic areas:
Polymorphic Post-Transplant Lymphoproliferative Disorder
Similarity Score4%
Reem Karmali, MD
Northwestern University
4 trials
Shared therapeutic areas:
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Worked with same sponsors:
National Cancer Institute (NCI)
Similarity Score4%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative DisorderMonomorphic Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder+4 more
All 1 trials loaded